Jeff Settleman

Jeff Settleman

UNVERIFIED PROFILE

Are you Jeff Settleman?   Register this Author

Register author
Jeff Settleman

Jeff Settleman

Publications by authors named "Jeff Settleman"

Are you Jeff Settleman?   Register this Author

59Publications

1539Reads

44Profile Views

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.

Cell Rep 2019 Oct;29(1):118-134.e8

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.08.090DOI Listing
October 2019

Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.

Mol Cancer Ther 2017 09 15;16(9):1729-1738. Epub 2017 Jun 15.

Department of Discovery Oncology, Genentech, South San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0009DOI Listing
September 2017

Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in mutant mesenchymal-like NSCLC cells.

Sci Signal 2017 Sep 12;10(496). Epub 2017 Sep 12.

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aam6291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657393PMC
September 2017

A three-drug combination to treat BRAF-mutant cancers.

Nat Med 2017 08;23(8):913-914

Calico Life Sciences, South San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4382DOI Listing
August 2017

Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.

Mol Cancer Ther 2017 04 30;16(4):694-704. Epub 2017 Jan 30.

Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-16-0504DOI Listing
April 2017

Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis.

Cell Metab 2016 11 8;24(5):753-761. Epub 2016 Sep 8.

Department of Discovery Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.cell.com/cell-metabolism/pdf/S1550-4131(16)30424-
Web Search
http://dx.doi.org/10.1016/j.cmet.2016.08.008DOI Listing
November 2016

TORquing metabolic reprogramming in cancer cells.

Cell Cycle 2016 09 30;15(18):2387-8. Epub 2016 Jun 30.

b Calico Life Sciences , South San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026797PMC
http://dx.doi.org/10.1080/15384101.2016.1204850DOI Listing
September 2016

Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.

Nat Commun 2016 08 3;7:12351. Epub 2016 Aug 3.

Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms12351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976141PMC
August 2016

Reproducible pharmacogenomic profiling of cancer cell line panels.

Nature 2016 05;533(7603):333-7

Department of Bioinformatics and Computational Biology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature17987DOI Listing
May 2016

mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.

Cancer Cell 2016 Apr 24;29(4):548-562. Epub 2016 Mar 24.

Department of Discovery Oncology, Genentech Inc, South San Francisco, CA 94080, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.018DOI Listing
April 2016

Communication in Drug Development: "Translating" Scientific Discovery.

Cell 2016 Mar;164(6):1101-1104

Calico Life Sciences, 1170 Veterans Boulevard, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2016.02.050DOI Listing
March 2016

Cancer: Bet on drug resistance.

Authors:
Jeff Settleman

Nature 2016 Jan 6;529(7586):289-90. Epub 2016 Jan 6.

Calico Life Sciences, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature16863DOI Listing
January 2016

Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Mol Cancer Res 2015 Apr 9;13(4):713-20. Epub 2015 Feb 9.

Laboratory of Cellular and Molecular Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-14-0570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410013PMC
April 2015

Predicting response to HER2 kinase inhibition.

Authors:
Jeff Settleman

Oncotarget 2015 Jan;6(2):588-9

Discovery Oncology, Genentech, Inc., South San Francisco, CA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359239PMC
http://dx.doi.org/10.18632/oncotarget.3036DOI Listing
January 2015

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.

Cancer Res 2014 Oct 14;74(20):5878-90. Epub 2014 Aug 14.

Department of Discovery Oncology, Genentech, South San Francisco, California.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-14-1009DOI Listing
October 2014

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

Cancer Cell 2014 Aug 24;26(2):207-21. Epub 2014 Jul 24.

Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.05.019DOI Listing
August 2014

Optimizing the treatment of BRAF mutant melanoma.

Authors:
Jeff Settleman

Genome Med 2014 28;6(4):30. Epub 2014 Apr 28.

Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/gm547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062054PMC
July 2014

From cancer genomics to precision oncology--tissue's still an issue.

Cell 2014 Jun;157(7):1509-14

Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2014.05.027DOI Listing
June 2014

EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.

Cancer Res 2014 May 19;74(10):2825-34. Epub 2014 Mar 19.

Authors' Affiliations: Department of Radiation Oncology, Massachusetts General Hospital; Center for Cancer Research, Massachusetts General Hospital Cancer Center; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden; OncoRay-National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden; Institute of Radiation Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden; and Cancer Consortium (DKTK) Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278592PMC
May 2014

Mechanisms of acquired resistance to targeted cancer therapies.

Future Oncol 2012 Aug;8(8):999-1014

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.86DOI Listing
August 2012

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.

Curr Opin Genet Dev 2012 Feb 7;22(1):45-9. Epub 2012 Feb 7.

Discovery Oncology, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gde.2012.01.003DOI Listing
February 2012

Dissecting cancer heterogeneity.

Nat Biotechnol 2011 Dec 8;29(12):1095-6. Epub 2011 Dec 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.2063DOI Listing
December 2011

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

Cancer Cell 2011 Aug;20(2):158-72

Massachusetts General Hospital Cancer Center and Harvard Medical School. Building 149, 13th Street, Charlestown, Boston, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2011.07.011DOI Listing
August 2011

Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".

Biochem Pharmacol 2010 Sep 6;80(5):666-73. Epub 2010 Mar 6.

Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2010.03.001DOI Listing
September 2010

Cancer: miRNA addiction - depending on life's little things.

Curr Biol 2010 Sep;20(18):R812-3

Genentech, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cub.2010.08.040DOI Listing
September 2010

Discovering tumor suppressor genes through genome-wide copy number analysis.

Curr Genomics 2010 Aug;11(5):297-310

Massachusetts General Hospital Cancer Center and Harvard Medical School, 149, 13th Street, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920210791616734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944996PMC
August 2010

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.

Nat Rev Cancer 2010 Apr 19;10(4):241-53. Epub 2010 Mar 19.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2820DOI Listing
April 2010

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.

Cancer Res 2010 Feb 2;70(4):1625-34. Epub 2010 Feb 2.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-3620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057521PMC
February 2010

Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Clin Cancer Res 2010 Jan 22;16(1):109-20. Epub 2009 Dec 22.

Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805048PMC
January 2010

Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?

BMC Med 2009 Dec 14;7:78. Epub 2009 Dec 14.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1741-7015-7-78DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799438PMC
December 2009

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

J Clin Oncol 2009 Nov 26;27(33):5650-9. Epub 2009 Oct 26.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.22.9054
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.22.9054DOI Listing
November 2009

Targeting the RAF-MEK-ERK pathway in cancer therapy.

Cancer Lett 2009 Oct 12;283(2):125-34. Epub 2009 Feb 12.

Medical Oncology Department and Cancer Research Program, Hospital del Mar-IMIM, Passeig Maritim 25-29, 08003 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2009.01.022DOI Listing
October 2009

A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.

Authors:
Jeff Settleman

Cancer Cell 2009 Oct;16(4):278-9

Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2009.09.013DOI Listing
October 2009

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.

Nat Rev Drug Discov 2009 Sep 24;8(9):709-23. Epub 2009 Jul 24.

Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2871DOI Listing
September 2009

Oncogenic K-ras "addiction" and synthetic lethality.

Cell Cycle 2009 Sep 23;8(17):2676-7. Epub 2009 Sep 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.8.17.9336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707179PMC
September 2009

Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).

Authors:
Jeff Settleman

Semin Oncol 2009 Apr;36(2 Suppl 1):S36-41

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2009.02.006DOI Listing
April 2009

Cancer: drivers and passengers.

Nature 2007 Mar;446(7132):145-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/446145aDOI Listing
March 2007

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Nat Genet 2005 Dec 30;37(12):1315-6. Epub 2005 Oct 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ng1671
Publisher Site
http://dx.doi.org/10.1038/ng1671DOI Listing
December 2005

p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling.

J Cell Sci 2005 Oct 27;118(Pt 20):4689-700. Epub 2005 Sep 27.

Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Candiolo, Torino 10060, Italy.

View Article

Download full-text PDF

Source
http://jcs.biologists.org/cgi/doi/10.1242/jcs.02590
Publisher Site
http://dx.doi.org/10.1242/jcs.02590DOI Listing
October 2005

DOCK4, a GTPase activator, is disrupted during tumorigenesis.

Cell 2003 Mar;112(5):673-84

Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0092-8674(03)00155-7DOI Listing
March 2003